Cagrilintide 5mg

Cagrilintide is a long-acting amylin analog studied in experimental research for its interaction with appetite-related neuroendocrine signaling and metabolic regulation pathways. Laboratory studies frequently examine its role in satiety signaling, peptide hormone receptor pharmacology, and central energy-balance mechanisms.

Cagrilintide (NNC0174-0833 / AM833) is a synthetic 37-amino-acid peptide derived from human amylin (islet amyloid polypeptide, IAPP). It has been engineered as a long-acting analog designed to interact with amylin receptors (AMYR) and calcitonin receptors (CTR), forming part of a class sometimes referred to as dual amylin receptor/calcitonin receptor agonists (DACRAs).

Molecular Mechanism Research

Amylin and Calcitonin Receptor Interaction

Amylin receptors consist of a calcitonin receptor core complexed with receptor activity-modifying proteins (RAMPs). Cagrilintide has been shown in experimental models to activate these receptor complexes, producing intracellular signaling events associated with satiety-related neuroendocrine pathways.

These receptor systems are highly expressed in several regions involved in metabolic signaling, including:

• the area postrema

• the nucleus tractus solitarius (NTS)

• hypothalamic nuclei associated with energy regulation

Activation of these receptors has been associated in experimental models with modulation of neural circuits involved in satiety signaling and nutrient-responsive feedback pathways.

Central Neuroendocrine Signaling

In preclinical research, cagrilintide has been examined for its influence on central nervous system signaling pathways that regulate energy balance.

Experimental observations suggest receptor activation within brainstem and hypothalamic regions may influence:

• satiety-related neuronal signaling

• hypothalamic appetite regulation pathways

• reward-related food signaling circuits

These neuroendocrine pathways are often studied in research investigating peptide hormone signaling involved in energy homeostasis.

Peripheral Signaling Pathways

Beyond central receptor activity, experimental studies have also reported additional signaling events associated with cagrilintide activity.

These include:

• cAMP signaling pathways

• phosphorylation events involving cellular ion transport proteins

• signaling interactions observed in renal epithelial transport models

Such observations are typically explored in preclinical studies examining peptide hormone signaling and metabolic regulatory pathways.

Structural Characteristics

Cagrilintide is a 37-amino-acid peptide analog derived from the endogenous amylin sequence. Structural modifications have been introduced to improve molecular stability and prolong receptor engagement in experimental models.

These modifications differentiate cagrilintide from earlier amylin analogs, which have also been used in research examining amylin receptor signaling.

Product description:

• Molecular Formula: C194H312N54O59S2
• Molecular Weight: 4409 g/mol
• CAS:  1415456-99-3
• Total Active Ingredient: 5 mg per vial – ( Vial format: lyophilized powder for enhanced stability.)

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.